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socAnticoagulation for atrial ﬁbrillation has become more complex due to the introduction of new anticoagulant agents, the
number and kinds of patients requiring therapy, and the interactions of those patients in the matrix of care. The man-
agement of anticoagulation has become a “team sport” involving multiple specialties in multiple sites of care. The
American College of Cardiology, through the College’s Anticoagulation Initiative, convened a roundtable of experts from
multiple specialties to discuss topics important to the management of patients requiring anticoagulation and to make
expert recommendations on issues such as the initiation and interruption of anticoagulation, quality of anticoagulation
care, management of major and minor bleeding, and treatment of special populations. The attendees continued to
work toward consensus on these topics, and present the key ﬁndings of this roundtable in a state-of- the-art review
focusing on the practical aspects of anticoagulation care for the patient with atrial ﬁbrillation. (J Am Coll Cardiol
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1341AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
AF = atrial ﬁbrillation
DOAC = direct-acting
oral anticoagulant
DAPT = dual antiplatelet
therapy
FFP = fresh frozen plasma
ICH = intracranial hemorrhage
INR = international
normalized ratio
OACT = oral anticoagulant
therapy
TTR = time in therapeutic
range
VKA = Vitamin K antagonistI n September 2013, following a series of pivotaltrials and drug approvals, the American Collegeof Cardiology (ACC) convened a roundtable dis-
cussion at the HeartHouse toaddressclinical issues re-
garding oral anticoagulant alternatives to warfarin in
patients with nonvalvular atrial ﬁbrillation (AF). The
meetingincludedrepresentativesofspecialtysocieties,
theU.S.FoodandDrugAdministration (FDA), industry,
andpatientadvocates (OnlineAppendix 1).Discussions
covered 4 general topics:
1. Initiation and interruption of anticoagulant
therapy;
2. Quality, cost, and team-based management of
anticoagulation;
3. Management of bleeding and emergency care; and
4. Complex disease states and special populations.
The discussion was supplemented with focused
reviews of the English language published data in
PubMed to November, 2014, that pertained to the
roundtable themes.
Data from the ACC’s PINNACLE Registry showed
large variations in the percentage of appropriate
anticoagulation for AF even before the introduction
of direct-acting oral anticoagulants (DOACs) (1).
Management of anticoagulation crosses the bounds of
specialty and type of practice (Central Illustration).
This review attempts to provide practical consensus
recommendations as well as to point out gaps in
knowledge and areas of future inquiry.
ASSESSING THE BENEFITS AND RISKS OF
ORAL ANTICOAGULANT AGENTS
Oral anticoagulant therapy (OACT) reduces stroke risk
in patients with nonvalvular AF. Patients with
valvular AF and those with prosthetic mechanical
heart valves or signiﬁcant (moderate to severe) mitral
stenosis were excluded from clinical trials, and
therefore, this document will not suggest changes in
their management. Patients with nonvalvular AF
(paroxysmal, persistent, or permanent) with or
without symptoms are all considered for OACT on the
basis of their individual risk proﬁle.
The 2014 AF guidelines recommend the use of the
CHA2DS2-VASc (Congestive heart failure or left ven-
tricular dysfunction; Hypertension; Age $75 years;
Diabetes mellitus; Stroke, transient ischemic attack,has received grant support from Janssen (to institution) and the National I
American College of Clinical Pharmacy, the National Blood Clot Alliance, an
Listen to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
You can also listen to this issue’s audio summary by JACC Editor-in-Chief D
Manuscript received November 27, 2014; revised manuscript received Januaor thromboembolism; Vascular disease; Age 65
to 74 years; Sex category) scoring system
(Table 1) (2) instead of CHADS2 (Congestive
heart failure, Hypertension, Age $75 years,
Diabetesmellitus, Stroke or transient ischemic
attack) (3), because it increases the number of
patients who meet criteria for anticoagulation
therapy while more accurately identifying
truly low-risk patients. Many patients
(women, those age 65 to 75 years, and patients
with vascular disease) are redistributed from
the low- to higher-risk categories (3).
Several bleeding risk scores are avail-
able, including HAS-BLED (Hypertension,
Abnormal renal or liver function, Stroke,
Bleeding, Labile INR, Elderly, Drugs and
alcohol) and ATRIA (Anticoagulation And
Risk Factors In Atrial Fibrillation) (4,5), which
may identify patients at higher risk of bleeding;
however, more information is needed on their
clinical utility (2). Tools, such as the AnticoagEvaluator
and the Stroke Prevention in Atrial Fibrillation Risk
Tool, are available at the point of care to estimate the
risk of stroke and beneﬁts of anticoagulation therapy
in patients with AF (6,7).
CLINICAL TRIALS COMPARING DOACs WITH
VITAMIN K ANTAGONISTS
There are 2 classes of DOACs: factor Xa (FXa) inhi-
bitors, such as rivaroxaban, apixaban and edoxaban;
and direct thrombin inhibitors, such as dabigatran.
Table 2 highlights selected trials comparing the safety
and efﬁcacy of DOACs to adjusted-dose warfarin with
target international normalized ratio (INR) of 2 to 3.
These trials have limitations, including non-
inferiority study designs and relatively short treat-
ment follow-up. The median time in therapeutic
range (TTR) for warfarin patients was #69% in each
of the trials; the results may have been different
if the patients had achieved a greater percentage of
TTR. Limited guidance is provided concerning the
potential advantage of using DOACs in patients taking
warfarin with TTR >75%. When data from the trials
are combined, DOACs appear to reduce stroke, intra-
cranial hemorrhage (ICH), and overall mortality
compared with warfarin, with similar major bleeding
risks. However, gastrointestinal bleeding appearsnstitutes of Health; and has a relationship with the
d the Anticoagulation Forum.
ntin Fuster.
r. Valentin Fuster.
ry 21, 2015, accepted January 29, 2015.
CENTRAL ILLUSTRATION Complex Interactions Surrounding the Anticoagulation Patient
•  Patients taking OACs will require baseline and periodic lab 
monitoring to determine dose
•  Coordinating care through anticoagulation clinics improves patient 
outcomes and reduces costs. Anticoagulation clinics need financial 
support from healthcare systems to be able to exist
•  The CHA2DS2-VASc scoring system helps clinicians determine 
stroke risk and to choose oral anticoagulation (OAC) therapy
•  OAC therapy options: New direct oral anticoagulants (DOAC) 
or vitamin K antagonists (VKA). The most commonly used VKA is warfarin
•  Drug interactions should also be considered when prescribing
Initiation of OAC to reduce stroke risk in patients with AF1
Anticoagulation therapy options
0 (low 
stroke risk)
1 
(moderate)
≥2
(high)
No antithrombotic therapy
(or aspirin 75–325 mg daily)
Either DOAC or warfarin at an international normalized ratio 
(INR) of 2.0-3.0
Either DOAC or warfarin at INR 2.0-3.0
Risk factor
C Congestive heart failure (or left ventricular systolic dysfunction) 1
H  Hypertension (blood pressure consistently above 140/90 mmHg) 1
A2 Age ≥75 years 2
D Diabetes Mellitus 1
S2 Prior Stroke or TIA or thromboembolism 2
V Vascular disease (peripheral artery disease, MI, aortic plaque) 1
A Age 65–74 years 1
Sc Sex category (i.e. female sex) 1
Quality, cost and team-based management 2
Management of bleeding and emergency care3
Even with coordinated care, bleeding complications can occur. 
Minor bleeding may predict major bleeding and may lead to stoppage
of effective OAC therapy. Major bleeding is associated with higher mortality.
There are specific recommendations for managing these scenarios:
•  Bleeding onset
•  Major bleeding
•  Clinically relevant non-major bleeding
•  Minor bleeding or elevated INR values
•  After bleeding
Total score
Points
Management of complex disease 4
Patients with AF requiring anticoagulation therapy often
have comorbid conditions 
There are specific recommendations for OAC use for these patients:
•  Recent coronary stent and new onset AF 
•  Established AF, on OACs, requiring elective stenting
•  Established AF, on OACs, who develop acute coronary syndrome
•  Established AF, on OACs, with medically managed coronary disease
•  Patients with stenting >1 month ago with a bare metal stent, 
or >6 months ago with a drug eluting stent, who develop AF
•  Cerebral vascular disease and AF
•  Previously on OACs, presenting with acute Ischemic stroke
•  Ischemic stroke treated with vitamin K antagonist – convalescent phase 
•  Hemorrhagic stroke, on OACs
•  Significant carotid stenosis and AF
•  Peripheral artery disease and AF
•  Mechanical heart valves and needing cardiac surgery
•  Cardioversion
•  AF ablation
Kovacs, R.J. et al. J Am Coll Cardiol. 2015; 65(13):1340–60.
New drugs, such as the direct-acting oral anticoagulants (DOACs), are tested for safety and efﬁcacy in clinical trials involving speciﬁc patient populations with rigorous
inclusion and exclusion criteria. Labels with prescribing instructions are written on the basis of those trial data and data from a limited number of supporting trials using
speciﬁc patient samples to test a limited number of drug interactions and a few select special patient populations. Once approved for use, these drugs are introduced
into a much more complex system of care. Patients taking DOACs move between hospital care and outpatient care and interact with many health care workers in a
complex system. Patients taking DOACs have multiple comorbidities and take DOACs for long periods of time. Coordination of care is of the utmost importance to
provide safe and effective management of oral anticoagulation in the modern health care environment. AF ¼ atrial ﬁbrillation; INR ¼ international normalized ratio;
MI ¼ myocardial infarction; OAC ¼ oral anticoagulants; TIA ¼ transient ischemic attack; VKA ¼ vitamin K antagonist.
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dabigatran when compared with warfarin (8).
THE RIGHT DRUG FOR THE RIGHT PATIENT
Appropriate drug selection depends on approved in-
dications, patient characteristics, concomitant medi-
cations, clinician and patient preference, and cost.
Therapy with well-managed warfarin and with high
TTR is appropriate for certain patients. Several re-
ports quantify the relationship between TTR andmajor clinical outcomes in patients with AF (9,10).
Patients with TTR <58% despite adequate warfarin
dosing adjustment may beneﬁt from a DOAC (11).
Clinical trials have also shown lower risks of ICH with
DOACs when compared with warfarin.
Individual response to warfarin varies with
age, sex, body mass index, concomitant medicines,
certain foods, and genotype. Warfarin has a rela-
tively narrow therapeutic index. Overdosing can
result in bleeding; underdosing can result in throm-
bosis. Patients treated with warfarin should have an
TABLE 1 The 2009 Birmingham Schema Expressed as a
Point-Based Scoring System, With the Acronym CHA2DS2–VASc
Risk Factor Score
Congestive heart failure or left ventricular dysfunction 1
Hypertension 1
Age $75 yrs 2
Diabetes mellitus 1
Stroke, transient ischemic attack, or thromboembolism 2
Vascular disease (prior myocardial infarction,
peripheral artery disease, or aortic plaque)
1
Age 65–74 yrs 1
Sex category (i.e., female) 1
Maximum total points 9
Reprinted with permission from Lip et al. (106).
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therapy and regular ongoing monitoring when INR is
stable and within range. Genetics inﬂuence vitamin
K antagonist (VKA) response; however, genetic
testing to predict VKA response has not been widely
adopted, nor has it been shown to be of value
in randomized trials (12,13). Home monitoring ofTABLE 2 Summary of Selected DOACs Clinical Trials
RE-LY (33)
(N ¼ 18,113) (3 arms)*
R
Drug, dose Dabigatran, 150 mg bid Rivarox
Adjusted dose? No Yes, at
15 m
30–
Design Randomized open-label Random
do
Mean age, yrs 71.5
Prior stroke/ transient ischemic
attack/systemic embolism
20%
Mean CHADS2 2.2
Warfarin-naïve 50.4%
Comparator warfarin INR 2–3 67% TTR (median) 58
Comparator Warfarin INR 2–3 64% TTR (mean) 55
Outcome, RR (95% CI)
Stroke/systemic embolism 0.66 (0.53–0.82) 0.
Ischemic stroke 0.76 (0.60–0.98) 0.
Hemorrhagic stroke 0.26 (0.14–0.49) 0.
Major bleeding 0.93 (0.81–1.07) 1.
Intracranial hemorrhage 0.40 (0.27–0.60) 0.
Gastrointestinal bleeding 1.50 (1.19–1.89) 1.
Cardiovascular mortality 0.85 (0.72–0.99) 0.
All-cause mortality 0.88 (0.77–1.00) 0.
Estimate creatinine clearance (CrCl) using Cockcroft-Gault formula: ([140 – age]  weigh
shown for edoxaban 60 mg daily.
CHADS2 ¼ Congestive heart failure, Hypertension, Age $75 years, Diabetes mellitus, S
anticoagulant; INR ¼ international normalized ratio; RR ¼ risk ratio; SCr ¼ serum creatinVKA therapy is reasonable in selected patients
(14), including those who have difﬁcult access to
laboratory services. Many insurance plans, including
Medicare, cover the cost of a device and once-weekly
use of test strips. Several nationwide VKA home
management services accept commercial and Medi-
care health insurance (15).
The DOACs’ mechanism of action, dosing informa-
tion, drug interactions, and recommended monitoring
schedules are listed in Table 3. Although DOACs are
more expensive than warfarin, advantages for some
patients include a lack of dietary limitations, fewer
drug interactions, and elimination of INR testing.
Patients taking OACs require baseline and periodic
laboratory monitoring (16). DOAC dosing is sensitive
to changes in renal function. A summary of dosing
changes relative to renal function can be found in
Table 3. Although many laboratories report renal
function as the estimated glomerular ﬁltration
rate, renal function should be estimated using the
Cockcroft-Gault equation ([(140  age)  weight
(in kg)  0.85 if female]/[72  creatinine (in mg/dl)])
to determine the appropriate DOAC dose.OCKET-AF (34)
(N ¼ 14,264)
ARISTOTLE (35)
(N ¼ 18,201)
ENGAGE AF-TIMI 48 (36)
(N ¼ 21,105) (3 arms)†
aban, 20 mg daily Apixaban, 5 mg bid Edoxaban, 60/30 mg daily
randomization only:
g daily if CrCl
49 ml/min
Yes, at randomization only:
2.5 mg bid if 2 of: age
$80 yrs, weight <60 kg,
SCr $1.5 mg/dl
Yes, at randomization and
during study: both doses halved
if any 1 of the following:
CrCl 30–50 ml/min, weight
#60 kg, use of verapamil,
quinidine, or dronedarone
ized double-blind,
uble-dummy
Randomized double-blind,
double-dummy
Randomized double-blind,
double-dummy
73 70 72
55% 19% 28%
3.5 2.1 2.8
37.6% 43% 41%
% TTR (median) 66% TTR (median) 68% (median)
% TTR (mean) 62% TTR (mean) 65% (mean)
88 (0.75–1.03) 0.79 (0.66–0.95) 0.88 (0.75–1.03)
94 (0.75–1.17) 0.92 (0.74–1.13) 1.00 (0.83–1.19)
59 (0.37–0.93) 0.51 (0.35–0.75) 0.54 (0.38–0.77)
04 (0.90–1.20) 0.69 (0.60–0.80) 0.80 (0.71–0.91)
67 (0.47–0.93) 0.42 (0.30–0.58) 0.47 (0.34–0.63)
39 (1.19–1.61) 0.89 (0.70–1.15) 1.23 (1.02–1.50)
89 (0.73–1.10) 0.89 (0.76–1.04) 0.86 (0.77–0.97)
85 (0.70–1.02) 0.89 (0.80–0.998) 0.92 (0.83–1.01)
t [in kg]  0.85 if female)/(72  creatinine [in mg/dl]). *Results are shown for dabigatran 150 mg bid. †Results are
troke or transient ischemic attack; CI ¼ conﬁdence interval; CrCl ¼ creatinine clearance; DOAC ¼ direct-acting oral
ine; TTR ¼ time in therapeutic range.
TABLE 3 FDA-Appro
Mechanism of action
Dosing for nonvalvular
Dosing considerations
nonvalvular AF with
renal adjustments
Dosing considerations
nonvalvular AF with
hepatic adjustment
Drug interactions
Major adverse effects
Monitoring§
*Other indications for thes
‡Estimate creatinine cleara
AF ¼ atrial ﬁbrillation;
PT ¼ prothrombin time.
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1344Patients with severe renal impairment were
excluded from the large phase III trials evaluating
DOACs, and therefore, warfarin remains the treat-
ment of choice for AF patients with severe renal
impairment or end-stage renal disease (2). However,
the FDA has approved apixaban in patients with
end-stage renal disease on hemodialysis on the basis
of pharmacokinetic modeling data.ved Direct Acting Oral Anticoagulants for Nonvalvular Arial Fibrillation*
Dabigatran (Pradaxa) (107) Rivaroxaban (Xarelto) (108)
Direct thrombin inhibitor Factor Xa inhibitor
AF† 150 mg twice daily 20 mg daily with
evening meal
for If CrCl‡ is 15–30 ml/min:
75 mg twice daily
If CrCl is <15 ml/min: avoid use
If CrCl‡ is 15–50 ml/min:
15 mg daily with
evening meal
for
s
Administration in patients with
moderate hepatic impairment
(Child-Pugh B) showed
no evidence of change in
exposure or pharmacodynamics
Avoid use in patients with
Child-Pugh B and C
hepatic impairment or
with any degree of
hepatic impairment
associated with
coagulopathy
Avoid concomitant use with
P-gp inducers (e.g., rifampin).
P-gp inhibitors and impaired
renal function can lead
to increased exposure
to dabigatran: avoid
concomitant use
with severe renal impairment
(<30 ml/min); for moderate
renal impairment reduce dose
to 75 mg twice daily when
used concomitantly with
dronedarone or systemic
ketoconazole
Avoid concomitant use with
strong dual inhibitors of
CYP3A4 and P-gp
(e.g., ketoconazole,
ritonavir, erythromycin)
or reduce apixaban dose
Avoid concomitant use with
strong dual inducers of
CYP3A4 and P-gp
(e.g., rifampin, phenytoin,
carbamazepine)
Avoid concomitant use with
other anticoagulants
Dyspepsia, bleeding Bleeding
Baseline laboratory assessment:
hemoglobin/hematocrit,
liver function, renal function,
PT/INR
At every visit: adherence,
signs/symptoms of bleeding or
thromboembolism, side effects,
concomitant medications
(including over-the-counter)
Annual laboratory assessment:
hemoglobin/hematocrit, renal
function, liver function
If CrCl 30–60 ml/min,
>75 years of age,
or fragile: renal function
q 6 months
If CrCl 15–30 ml/min: renal
function q 3 months
If condition changes that
might affect anticoagulation
therapy: check renal
and/or liver function
e agents are not included in this table. Refer to the prescribing information for complete info
nce (CrCl) using Cockcroft-Gault formula: ([140 – age]  weight [in kg]  0.85 if female)/
CrCl ¼ creatinine clearance; CYP3A4 ¼ cytochrome P450 3A4; INR ¼ international normDRUG INTERACTIONS
Drug interactions should be considered when pre-
scribing any OACT (Tables 3 and 4). All patients should
be instructed to alert the clinician prescribing the
OACT any time changes in other medications are
made (Table 5). Warfarin has many food and drug
interactions (17), although some are not wellApixaban (Eliquis) (109) Edoxaban (Savaysa) (24)
Factor Xa inhibitor Factor Xa inhibitor
5 mg twice daily If CrCl‡ >50 ml/min to
#95 ml/min: 60 mg daily
If the patient has at
least 2 of the following:
- Age $80 years old
- Weight #60 kg
- SCr $1.5 mg/dl: 2.5 mg
twice daily
If CrCl‡ >95 ml/min:
do not use; may have an
increased risk of ischemic
stroke as compared with warfarin
If CrCl‡ 15–50 ml/min: 30 mg daily
Mild hepatic impairment:
no dose adjustment needed
Moderate hepatic impairment:
no dosing recommendation
available
Severe hepatic impairment:
avoid use
Avoid use in patients with
Child-Pugh B and C
hepatic impairment
Avoid concomitant use with
strong dual inhibitors of
CYP3A4 and P-gp
(e.g., ketoconazole,
ritonavir, erythromycin)
or reduce apixaban dose
Avoid concomitant use with
strong dual inducers of
CYP3A4 and P-gp
(e.g., rifampin, phenytoin,
carbamazepine)
Concomitant use with
antiplatelet agents,
ﬁbrinolytic agents,
heparin, aspirin, and chronic
NSAID increases bleeding risk
Avoid concomitant use with
P-gp inducers (e.g., rifampin)
Bleeding Bleeding
rmation. †May need to adjust dose or avoid on the basis of concomitant medications.
(72  creatinine [in mg/dl]). §Adapted from Heidbuchel et al. (16).
alized ratio; NSAID ¼ nonsteroidal anti-inﬂammatory drug; P-gp ¼ P-glycoprotein;
TABLE 4 Selected Drug Interactions With Direct Acting Oral Anticoagulants*
Mechanism of Drug Interaction Dabigatran (Pradaxa) (107)
Rivaroxaban
(Xarelto) (108) Apixaban (Eliquis) (109) Edoxaban (Savaysa) (24)
Carbamazepine Strong inducer of CYP3A4
and P-gp
Avoid use Avoid use Avoid use No speciﬁc recommendations
Clarithromycin Strong inhibition of CYP3A4
and P-gp
No adjustment needed No adjustment
needed
Reduce dose from 5 mg twice
daily to 2.5 mg twice daily
If on 2.5 mg twice daily,
discontinue apixaban
No speciﬁc recommendations
Dronedarone P-gp inhibitor With CrCl 30–50 ml/min,
reduce dose to 75 mg
twice daily
No speciﬁc
recommendations
No speciﬁc recommendations No adjustment needed
Itraconazole Strong inhibition of CYP3A4
and P-gp
No adjustment needed Avoid use Reduce dose from 5 mg twice
daily to 2.5 mg twice daily
If on 2.5 mg twice daily,
discontinue apixaban
No speciﬁc recommendations
Ketoconazole Strong inhibition of CYP3A4
and P-gp
With CrCl 30–50 ml/min,
reduce dose to 75 mg
twice daily
Avoid use Reduce dose from 5 mg twice
daily to 2.5 mg twice daily
If on 2.5 mg twice daily,
discontinue apixaban
No speciﬁc recommendations
Phenytoin Strong inducer of CYP3A4
and P-gp
Avoid use Avoid use Avoid use No speciﬁc recommendations
Rifampin Strong inducer of CYP3A4
and P-gp
Avoid use Avoid use Avoid use Avoid use
Ritonavir Strong inhibition of CYP3A4
and P-gp
No adjustment needed Avoid use Reduce dose from 5 mg twice
daily to 2.5 mg twice daily
If on 2.5 mg twice daily,
discontinue apixaban
No speciﬁc recommendations
St. John’s wort Strong inducer of CYP3A4
and P-gp
Avoid use Avoid use Avoid use No speciﬁc recommendations
*This is not a comprehensive list of all drug interactions. Please refer to individual medication manufacturer prescribing information for complete information. Estimate creatinine clearance (CrCl) using
Cockcroft-Gault formula: ([140 – age]  weight [in kg]  0.85 if female)/(72  creatinine [in mg/dl]).
Abbreviations as in Table 3.
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1345documented. Nonprescription medications (e.g., ace-
taminophen, ﬁsh oil, herbal supplements, and grape-
fruit juice) can potentiate the effect of VKAs (18–21).
DOACs are also subject to drug interactions. Rivar-
oxaban and apixaban interact with drugs that are
strong cytochrome P450 3A4 inhibitors or inducers and
are impacted by the efﬂux transporter P-glycoprotein
(22). Rifampin, a P-glycoprotein inducer, should not be
used with edoxaban or dabigatran. Medications that
inhibit the P-glycoprotein system increase dabigatran
and edoxaban plasma concentrations. Concomitant
use of quinidine, dronedarone, or verapamil with
edoxaban signiﬁcantly increases edoxaban exposure
(23). Although the dose of edoxaban was reduced by
50% in patients taking concomitant verapamil, quini-
dine, or dronedarone in ENGAGEAF-TIMI 48 (Effective
Anticoagulation with Factor Xa Next Generation in
Atrial Fibrillation-Thrombolysis In Myocardial Infarc-
tion 48), the FDA does not recommend dose reduction
in patients who are taking concomitant P-gp inhibitors
(24). Patients taking antiretroviral therapy, cyclo-
sporine, azole antifungals, and macrolides were
excluded from ENGAGE AF-TIMI 48, and the use of
these agents in patients taking DOACs should be
avoided as they increase edoxaban concentrations.INTERRUPTION OF DRUG THERAPY
Short-term interruption of OACT is safe for most low-
risk invasive procedures. Management of OACT
should be individualized for patients at higher
thromboembolic risk who are undergoing high-risk
procedures. Procedures that pose a high risk of
bleeding include intracranial, intraspinal, retroperi-
toneal, or intrathoracic surgery. Intraocular pro-
cedures and neuraxial anesthesia may present risks to
patients with even minor bleeding. Bridging with a
parenteral agent (e.g., unfractionated heparin or
low-molecular-weight heparin) is common, but the
data on prevention of embolic events are limited, and
the rate of bleeding is signiﬁcantly increased (25). The
decision to bridge must balance the risk of an embolic
event against the risk of bleeding (26).
TRANSITIONING BETWEEN
ANTICOAGULANT AGENTS
The INR monitoring is needed when transitioning
patients from VKA to a DOAC to avoid over-
anticoagulation. INR targets when switching from
warfarin to a DOAC are summarized in Table 4. If
TABLE 5 Transitioning Between Anticoagulants and Interruption of Therapy*
Conversion Apixaban (Eliquis) (109) Rivaroxaban (Xarelto) (108) Dabigatran (Pradaxa) (107) Edoxaban (Savaysa) (24)
From warfarin to DOAC Stop warfarin and start
apixaban when INR <2
Stop warfarin and start
rivaroxaban when INR
<3 (108)
Stop warfarin, start
dabigatran when INR <2
Stop warfarin and start
edoxaban when INR #2.5
From DOAC to warfarin† Stop apixaban and start warfarin
and parenteral anticoagulant
when next dose of apixaban
would be due; discontinue
parenteral agent when INR in
therapeutic range
Stop rivaroxaban and start
warfarin and parenteral
anticoagulant when
next dose of rivaroxaban
would be due; discontinue
parenteral agent when INR
in therapeutic range
If CrCl $50 ml/min, start
warfarin 3 days before
stopping dabigatran
If CrCl 30–50 ml/min, start
warfarin 2 days before
stopping dabigatran
If CrCl 15–30 ml/min, start
warfarin 1 day before
stopping dabigatran
If CrCl <15 ml/min, no
available recommendation
Oral option: reduce edoxaban
dose by 50% and start
warfarin; check INR at
least weekly and just
prior to edoxaban dose.
When INR $2, discontinue
edoxaban.
Parenteral option: stop
edoxaban; start parenteral
anticoagulant and warfarin
at time the next dose of
edoxaban would be due.
When INR $2, discontinue
edoxaban.
From parenteral agent
to DOAC
Discontinue parenteral agent;
start apixaban at the time
the next dose of parenteral
agent would be due
LMWH: discontinue LMWH;
start rivaroxaban 0–2 h
before next scheduled
evening dose of LMWH
and omit administration
of LMWH
Unfractionated heparin
intravenous infusion:
initiate rivaroxaban when
discontinuing heparin infusion
LMWH: discontinue LMWH;
start dabigatran 0–2 h
before the time the
next dose of LMWH
would be due.
Unfractionated heparin
intravenous infusion:
initiate dabigatran
when discontinuing
heparin infusion
LMWH: discontinue LMWH;
start edoxaban at the
time the next dose of
LMWH would be due.
Unfractionated heparin
intravenous infusion:
initiate edoxaban 4 h
after discontinuing
heparin infusion
From DOAC to parenteral
anticoagulant
Discontinue apixaban; start
parenteral agent at the time
the next dose of apixaban
would be due
Discontinue rivaroxaban;
start parenteral agent
at the time the next dose
of rivaroxaban would be due
If CrCl $30 ml/min;
discontinue dabigatran;
start parenteral agent
12 h after last dabigatran
dose
If CrCl <30 ml/min; discontinue
dabigatran; start parenteral
agent 24 h after last
dabigatran dose
Discontinue edoxaban;
start parenteral agent
at the time the next dose
of edoxaban would be due
From DOAC to DOAC Discontinue apixaban; start DOAC
at the time the next dose of
apixaban would be due
Discontinue rivaroxaban;
start DOAC at the time
the next dose of
rivaroxaban would be due
No information available;
consider patient speciﬁc
characteristics (e.g., renal
function, risk of bleeding
or stroke)
Discontinue edoxaban;
start DOAC at the time
the next dose of edoxaban
would be due
Temporary interruption of
DOAC for surgery and
other invasive procedures
Moderate–High-Risk Bleeding:
discontinue at least 48 h prior
to surgery or invasive procedure
Low-Risk Bleeding: Discontinue
at least 24 h prior to surgery or
invasive procedure
Discontinue at least 24 h
prior to surgery or
invasive procedure
If CrCl $50 ml/min: discontinue
at least 1–2 days prior
to surgery or invasive
procedure
If CrCl <50 ml/min: Discontinue
at least 3–5 days prior
to surgery or invasive procedure
Discontinue at least 24 h prior
to surgery or invasive
procedure
*Refer to the prescribing information for complete information. †DOACs can affect INR, so INR monitoring during conversion from DOAC to warfarin is not clinically useful. Estimate creatinine clearance (CrCl)
using Cockcroft-Gault formula: ([140 – age]  weight [in kg]  0.85 if female)/(72  creatinine [in mg/dl]).
DOAC ¼ direct-acting oral anticoagulant; other abbreviations as in Table 3.
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acting parenteral agent or a lower dose of the DOAC
may be needed. INR should be at least twice weekly,
and VKA dose should be adjusted using a reliable al-
gorithm until the INR reaches 2.0 to avoid excess
bleeding or thrombotic events (27). When transition-
ing from parenteral agents to DOACs, the DOACs can
be initiated up to 2 h before the next dose of the
parenteral agent or when stopping the intravenous
(IV) infusion. For those patients transitioning from
FXa inhibitors to parenteral agents, the parenteral
agents can be started at the intended time for thenext dose of FXa inhibitor. When converting from
dabigatran to a parenteral agent, the starting time
is dependent on the patient’s creatinine clearance
(Table 5).
LONG-TERM MANAGEMENT OF OACT
National guidelines and regulatory agencies en-
dorse coordinated-care anticoagulation management
models to maximize patient outcomes (14,28–31).
Despite data showing that coordinating care
through anticoagulation clinics (ACs) improves
TABLE 6 Education Topics for Oral Anticoagulants
VKA and DOACS
Anticoagulation basics Reason for anticoagulation
How medication reduces AF complications
Generic, trade names
Onset, duration of action
Duration of therapy
Reversibility
Storage
Adherence When to take doses
What to do if a dose is missed
Do not run out of this medication; consequence
of nonadherence
Consequence of taking too much
Risk and beneﬁts Common signs and symptoms of clot;
what to do if they occur
Common signs and symptoms of bleeding;
what to do if they occur
Need for birth control in women of childbearing age
Preventative care Precautionary measures to minimize risk
of trauma or bleeding
Potential drug interactions; which providers to notify
when medication regimen changes
Alcohol Avoid/limit alcohol intake
Aspirin Avoid unless clearly indicated
NSAIDs Avoid or minimize use
Self-care Common adverse effects, allergic reactions
Accessing health care Which providers to notify of anticoagulant use
Which providers to notify when dental, surgical, or
invasive procedures are scheduled
Carrying identiﬁcation (medication bracelet or
necklace, wallet card)
General laboratory monitoring Frequency, what will be checked
Dabigatran Only
Adherence Swallow whole, do not break, crush, or open capsule.
Take with full glass of water.
Storage Keep in original container; do not put in pillbox
(do not discard desiccant)
Self-care May increase GI upset; discuss with clinician if
bothersome.
Rivaroxaban Only
Adherence Take with food (evening meal)
VKA Only
Diet Inﬂuence of dietary vitamin K, need for consistency
INR monitoring Meaning, signiﬁcance, target
Frequency
GI ¼ gastrointestinal; VKA ¼ vitamin K antagonist; other abbreviations as in Tables 3 and 5.
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with usual medical care (14,28,29), only 30% to
40% of patients taking VKAs are managed in an
AC (32).
The scope of AC services should include man-
agement of DOACs (32). Therapy with both DOACs
and VKAs requires continual patient education
(Table 6), evaluation for drug interactions, and pe-
riodic laboratory monitoring (Table 3), all of which
could be coordinated through institutional protocols
or through ACs that facilitate initiation, compliance,
transition between agents, and interruption for
procedures.
MANAGEMENT OF BLEEDING AND
EMERGENCY CARE
Even with the best coordinated care, bleeding com-
plications will occur. Clinical trials comparing VKA
with DOACs for stroke prevention in AF have shown
an annual rate of major bleeding ranging from 2.1%
to 3.6% of patients. Fatal bleeding occurs in up to
0.5% (33–36). Major bleeding is associated with
higher mortality. In an analysis of 5 phase III clinical
trials, 30-day mortality after a major bleeding
episode was 13% with warfarin and 9% with dabi-
gatran (37).
Minor bleeding may predict major bleeding (5,38)
and may lead to discontinuation of effective anti-
coagulation therapy, underscoring the importance of
both preventing and effectively managing bleeding
episodes. With VKA therapy, regular monitoring and
appropriate dose adjustment will improve anti-
coagulation quality and reduce bleeding. For DOACs,
adjustment of dose on the basis of renal function is
crucial. With both VKA and DOACs, avoidance of
concomitant aspirin and other antiplatelet agents,
including long-acting NSAIDs, whenever possible, is
important.
BLEEDING DEFINITIONS
Bleeding severity in outpatient trials of anti-
coagulation was deﬁned by the International Society
on Thrombosis and Haemostasis (39) and has been
revised (40). For this review, those deﬁnitions have
been modiﬁed to enhance their clinical relevance
(Figure 1).
GENERAL ASSESSMENT OF THE
BLEEDING PATIENT RECEIVING OACT
Management of the bleeding patient taking an anti-
coagulant is outlined in Figure 2. Basic assessment
includes determination of the site, onset, and volumeof bleeding, and whether bleeding is ongoing.
The time of last ingestion of the anticoagulant is
especially important with DOACs. Concomitant med-
ications should be reviewed (Table 3). An assessment
of comorbid conditions and evidence of cardiac
decompensation should be done. Laboratory assess-
ment includes a complete blood count with platelet
count, prothrombin time (PT) and activated partial
thromboplastin time (aPTT), serum electrolytes, and
renal and hepatic function.
FIGURE 1 Deﬁnitions of Bleeding
Major Bleeding
Involves major organ including central nervous system
bleeding (intracranial or epidural), pericardial, intraocular,
retroperitoneal, intra-articular, intramuscular with 
compartment  syndrome
Clinically overt bleeding with a drop in hemoglobin of at
least 2 g/dl
Requires transfusion of at least 2 units
Requires surgical correction
Requires intravenous vasoactive agents
Minor Bleeding
Self- terminating
Does not require an office visit
No hospitalization or treatment by a health care
professional
Clinically Relevant Non-Major Bleeding
hospitalization or increased level of care, or
prompt physician guided medical or surgical treatment, or
Clinically overt bleeding that does not satisfy criteria for major
bleeding but requires:
a change in antithrombotic therapy
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VKA-TREATED PATIENTS. The PT/INR is essential to
the assessment of the VKA-treated patient with
bleeding. Invasive procedures to deﬁne and correct
the bleeding source are often delayed until the INR is
reduced. The type and amount of reversal agent is
often determined on the basis of the degree of PT
prolongation, although there are few data correlating
clinical outcomes with the initial INR level and few
data correlating clinical improvement with the use of
reversal agents.
DOAC-TREATED PATIENTS. Figure 3 summarizes the
potential use of coagulation assays in the assessment
of the bleeding patient taking a DOAC (41). A pro-
longed aPTT indicates an anticoagulant effect of
dabigatran, and a prolonged PT indicates an antico-
agulant effect of the FXa inhibitors. However,
elevated plasma levels of dabigatran and FXa in-
hibitors may occur with normal aPTT or PT values,
making them less useful in the assessment of the
bleeding patient. Different PT and aPTT reagents vary
widely in their sensitivity to the DOACs.
Furthermore, there may be some danger in relying
on conventional parameters to deﬁne reversal ther-
apy in a bleeding patient receiving a DOAC. For
example, an aPTT of >2.5 control suggests a supra-
therapeutic dabigatran concentration (42). A reversal
agent may take several hours to reach the patientafter ordering. Because the half-life of dabigatran is
relatively short, by the time a reversal agent is
administered, the reversal drug dose may be exces-
sive, resulting in clotting. This highlights 1 of the
difﬁculties in the design of clinical trials to assess
reversal agents (43).
The dilute thrombin time, a functional test of the
effect of thrombin on ﬁbrin formation, provides a
reasonable estimate of dabigatran concentration
across a wide range of drug levels (42), and is
commercially available (Hemoclot HYPHEN BioMed,
Neuville-sur-Oise, France). Ecarin-based assays, in-
cluding the ecarin clotting time and chromogenic
ecarin assays, correlate well with dabigatran con-
centration, but are not widely available.
The anticoagulant effect of FXa inhibitors can be
assessed by anti-FXa levels. Data linking anti-FXa
levels with bleeding and thrombosis related to
FXa inhibitors are unavailable. Calibration of anti-
factor Xa assays with speciﬁc FXa inhibitors is
recommended.
AGENTS TO REVERSE ANTICOAGULATION
The introduction of DOACs has made therapy to
reverse anticoagulation more complex. Newer agents
(such as prothrombin complex concentrate [PCC]) are
expensive and not always readily available. Many in-
stitutions have developed protocols for management
of the patient treated with OACT who experiences
major bleeding. Consultation with a hematologist is
recommended.
VITAMIN K. VKAs reduce the synthesis of functional
vitamin K–dependent coagulation factors, providing a
rationale for vitamin K therapy as a reversal agent. IV
vitamin K does not begin to reduce INR for 6 h, often
taking longer than 24 h for complete reversal (44). IV
vitamin K may result in allergic reactions (particularly
when given as a bolus), and IV infusions should
generally be limited to patients with major bleeding.
Subcutaneous and intramuscular administration is not
recommended. Oral vitamin K is used for minor
bleeding with an elevated INR. Although effective at
lowering the INR, there are few data demonstrating
improvement in outcomes with vitamin K. High
doses of vitamin K will prolong the time to achieve
a therapeutic INR when warfarin is restarted. Vitamin
K does not reverse the anticoagulant effect of DOACs.
FRESH FROZEN PLASMA. Fresh frozen plasma (FFP)
and blood transfusion provide volume, which is a
potential advantage in a volume-depleted patient,
but a potential disadvantage in patients with heart
failure or renal dysfunction. FFP is readily available,
although there are delays associated with thawing
FIGURE 2 Acute Management of Bleeding in a Patient Receiving Oral Anticoagulation
Step 4 Reverse
Step 3 Repair
Assess need for Surgery
Direct acting oral anticoagulants
Consider 4 factor prothrombin
complex concentrate
Platelet transfusion (for
thrombocytopenia or if patient
received antiplatelets)
Vitamin K antagonists
Vitamin K
Platelet transfusion (for
thrombocytopenia or if patients
received antiplatelets)
4-factor prothrombin complex
concentrate 
Consider FFP for poor
hemodynamic condition 
Step 2 Remove
Gastric lavage for recent
Ingestion (DOACs)
Dialysis (dabigatran)
Oral charcoal
Step 1 Review
Stop anticoagulation and antiplatelet therapy
Maintain organ perfusion
Volume resuscitation
Pressors
Identify source of bleeding
Evaluate for transfusion
Order baseline laboratory parameters including CBC
with platelets, renal function tests, PT, aPTT
Review time of last dose of anticoagulant
Assess for comorbid conditions, check for evidence of
cardiac decompensation
Review medications including aspirin, P2Y12 inhibitors,
NSAIDs, P-gp inhibitors, CYP3A4 inhibitors
All patients receive a basic level of care (periwinkle box) with additional care provided depending upon the degree of bleeding (gold and
salmon boxes). apTT ¼ activated partial thromboplastin time; CBC ¼ complete blood count; CYP3A4 ¼ Cytochrome P450 3A4; DOAC ¼ direct
oral anticoagulant; FFP ¼ fresh frozen plasma; NSAID ¼ nonsteroidal anti-inﬂammatory drug; P-gp ¼ P-glycoprotein; PT ¼ prothrombin time.
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actively bleeding, it may be necessary to administer
>1,500 ml of FFP to meaningfully increase coagula-
tion factors. Even with a reduction in INR, there are
few data showing improvement in outcomes with
FFP. FFP in clinically-feasible quantities does not
reverse the anticoagulant effect of DOACs.PROTHROMBIN COMPLEX CONCENTRATE. For pa-
tients with an elevated INR receiving VKA, a 10 to
30 min infusion of PCC improves INR values within
minutes and lasts for 12 to 24 h. The half-lives of
infused factors are similar to endogenous factors.
Vitamin K is generally recommended for use with PCC
to sustain the reversal effect.
FIGURE 3 Laboratory Testing for Anticoagulant Activity
Below on-
therapy range
Dabigatran
thrombin time
prothrombin time
prothrombin time
Anti-Xa Activity
activated partial thromboplastin time
activated partial thromboplastin time
prothrombin time
prothrombin time
Anti-Xa Activity
Anti-Xa Activity
activated partial thromboplastin time
activated partial thromboplastin time
Dilute thrombin time, ecarin clotting time,
Rivaroxaban
Apixaban
Edoxaban
 On-therapy
 range
 Above on-
therapy range
Periwinkle bars correspond to the approximate range of detectability (i.e., sensitivity) and
vertical hatching to the approximate range over which drug plasma levels may be quan-
tiﬁed (i.e., linearity) of each assay to below, within, and above typical on-therapy plasma
concentrations of direct oral anticoagulants (41).
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different DOACs. PCC did not normalize the aPTT,
ecarin clotting time, and thrombin time in healthy
volunteers who had received dabigatran, but imme-
diately reversed a prolonged PT and an abnormal
thrombin potential in rivaroxaban-treated healthy
volunteers (45). Studies show that reversal of an
anticoagulation effect can occur within 15 min, but
may differ between direct thrombin inhibitors and
FXa inhibitors. Recent studies show that PCC reverses
anticoagulant activity in healthy volunteers given
either dabigatran or rivaroxaban within 2 h (46). The
composition of PCC varies with the manufacturer.
The 4-factor PCC contains factors II, VII, IX, and X.
The 3-factor PCC contains little or no factor VII.
In healthy volunteers who received rivaroxaban,
3-factor PCC restored thrombin generation better
than 4-factor PCC, but 4-factor PCC produced largerreductions in mean prothrombin time within 30 min.
These discrepancies may be related to differences in
factor concentration in these agents (47).
Data linking improved clinical outcomes with the
use of PCC in DOAC-treated patients are lacking. In
addition, there is concern about myocardial infarction
(MI) and arterial thromboembolism with the more
potent agents (48,49) that must be balanced against
potential beneﬁts. Some forms of PCC contain hepa-
rin, a concern in patients with heparin-induced
thrombocytopenia. The dose of PCC is 20 to 50 U/kg,
and the wholesale cost is about $1.25/U.
OTHER REVERSAL AGENTS. Recombinant factor VIIa
has been effective for reversal of the anticoagulant
effect of VKA (50–52). Impact on laboratory parame-
ters occurs within minutes and lasts 2 to 6 h, but the
effect on bleeding consequences remains to be
determined (53), and there is concern about the risk
of thrombosis (48).
Three additional reversal agents are currently being
evaluated. Idarucizumab, a speciﬁc antibody to dabi-
gatran, has been reported to restore systemic blood
coagulation in animal studies (43) and in healthy
volunteers. The REVERSE-AD (A study of the Reversal
Effects of Idarucizumab on Active Dabigatran) trial
studying the use of this agent in uncontrolled bleed-
ing is underway. Andexanet alfa, a modiﬁed FXa
molecule that binds to FXa inhibitor allowing the pa-
tient’s intrinsic FXa to participate in coagulation, has
been reported to provide rapid and near-complete
reversal of factor X inhibitors in healthy volunteers.
Aripazine, a small synthetic molecule with broad ac-
tivity against heparin products and factor X agents, is
undergoing testing in healthy subjects (54).
MANAGEMENT OF MAJOR BLEEDING
Standard measures in the management of major
bleeding in a patient taking an oral anticoagulant
include ﬂuid and blood resuscitation, identiﬁcation
and treatment of the bleeding source, and avoidance
of administration of additional antithrombotic agents
or antiplatelet drugs. Prompt reversal of the anti-
thrombotic effects is desirable.
VITAMIN K ANTAGONISTS. Reversal of antico-
agulation should be considered in a patient receiving
VKAs who has major bleeding and an INR $1.5.
Vitamin K 5 to 10 mg should be administered by slow
IV infusion (14).
In 40 patients with a mean INR of 9.4, low-dose
3-factor PCC (25 U/kg) and high-dose 3-factor PCC (50
U/kg) lowered the INR by 50% and 43%, respectively
(55). Adding plasma further reduced the INR by 89%
and 88%. In another randomized study, 4-factor PCC
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with warfarin-associated bleeding (mean INR 3.7).
Within 1 h of the start of infusion,more than two-thirds
of the 4-factor PCC group had an INR <1.3 compared
with none in the FFP group (56).
The use of PCC is recommended as ﬁrst-line ther-
apy in patients taking VKAs with life-threatening
major bleeding (14). Doses can be repeated in 6 h.
Delays in the administration of PCC have been re-
ported (57), perhaps reﬂecting a lack of familiarity
with new therapies or the lack of ready availability of
these products.
DIRECT-ACTING ORAL ANTICOAGULANT AGENTS.
Gastric lavage could be considered for patients who
experience major bleeding, if DOAC ingestion has
been recent. Administration of activated charcoal
may be helpful if the DOAC has been ingested within
2 to 6 h (58).
Data on patients treated with DOACs who have
major bleeding are limited. Given the poor prognosis
of major bleeding, especially CNS bleeding, in pa-
tients treated with DOACs, some recommend PCC,
activated PCC, or as a last choice, activated factor VIIa
to treat severe or life-threatening bleeding (59).
However, there is no clinical evidence to support this
recommendation.
Because dabigatran is approximately 35% plasma-
bound, dialysis is a consideration in the event of
major bleeding, particularly in the setting of renal
insufﬁciency. Rivaroxaban, apixaban, and edoxaban
are highly protein-bound, and hemodialysis is likely
to be ineffective.
A high mortality rate associated with ICH occurs
regardless of the type of anticoagulant. Measures to
reverse the anticoagulant effect of VKAs have been
shown to improve INR values but not clinical out-
comes. Agents to reverse the anticoagulant effect of
DOACs are in development, but there is concern that
after ICH has occurred, even timely reversal of the
anticoagulant effect may not improve clinical
outcomes.
MANAGEMENT OF CLINICALLY-RELEVANT
NONMAJOR BLEEDING
VITAMIN K ANTAGONISTS. The use of reversal
agents in patients with clinically-relevant nonmajor
bleeding depends on the age of the patient, the
amount of bleeding, whether bleeding is ongoing, the
INR, the severity of anemia, and comorbid conditions
of the patient. Oral vitamin K could be considered in
this situation (14) but the risks of a prolonged period
of time with subtherapeutic INR values must be
weighed against the beneﬁts. Determining andtreating the cause of bleeding is important, so that
anticoagulation can be safely resumed.
DIRECT-ACTING ORAL ANTICOAGULANT AGENTS.
Given the short half-life of DOACs, the potential
thrombotic risk of nonspeciﬁc reversal agents, and
the lack of evidence to support their use, reversal
agents are not recommended for patients with
clinically-relevant nonmajor bleeding (59).
MANAGEMENT OF MINOR BLEEDING OR
ELEVATED INR VALUES
VITAMIN K ANTAGONISTS. In a patient with minor
bleeding, decisions on warfarin dosing should be
made dependent upon the INR.
If the INR is >10, management includes the
following steps: 1) stop VKA therapy; 2) administer 2.5
to 5 mg of oral vitamin K (13); 3) monitor the INR
every 12 to 14 h; and 4) restart VKA therapy as INR
approaches therapeutic range.
If the patient is at high risk for bleeding on the
basis of advanced age, recent bleeding, anemia, heart
failure, malignancy, renal dysfunction, and other
variables (60), oral vitamin K can be considered in the
nonbleeding patient with an INR >10. In a non-
bleeding patient with an INR >4.5 and <10, VKA
should be held for 1 or 2 doses. Data on bleeding risk
are conﬂicting in this situation (61,62). Vitamin K is
generally not recommended unless there are patient-
speciﬁc reasons that make bleeding more likely as
previously outlined.
DIRECT-ACTING ORAL ANTICOAGULANTS. Given
DOACs have short half-lives, and for patients with
minor bleeding, omitting several doses of the anti-
coagulant may be the only therapy required beyond
local measures (e.g., applying pressure). The duration
of DOAC hiatus depends on the amount of bleeding
and the thromboembolic risk.
MANAGEMENT AFTER BLEEDING
Patients recovering from major bleeding are fre-
quently anemic, but are at risk for future bleeding
(5). Resumption of anticoagulant therapy in such pa-
tients is problematic, and yet, these patients may also
be at high risk of thromboembolic events (63). In 1
study of 442 patients with a gastrointestinal bleed
associated with warfarin, 260 (58.8%) restarted
warfarin, sometimes as early as 4 days later (64).
Those patients who did not resume warfarin had a
higher risk of death and thromboembolic events.
Similar ﬁndings were noted in patients after warfarin-
associated CNS bleeding. Of 284 patients, 91 (32%)
were restarted on warfarin prior to hospital discharge.
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tients who were restarted on warfarin had lower
mortality and had no increase in bleeding (65). After
major bleeding, the location and severity of bleeding
and whether the source of bleeding was effectively
treated affects the decision of when and if anti-
coagulation should be restarted.
VKA-TREATED PATIENTS. If bleeding occurred in a
VKA-treated patient with a high INR who is at high
risk for stroke, a reasonable course of action after
resolution of the bleeding episode might be to restart
warfarin with careful follow-up of INR values. If a
drug interaction with warfarin can be identiﬁed and
avoided, VKAs can be restarted with more conﬁ-
dence. Alternatively, if the bleeding was not gastro-
intestinal or the TTR was low, it may be appropriate
to substitute a DOAC for warfarin therapy. Recent
guidelines suggest the use of antiplatelet agents in
this situation, although at a Class IIb level of recom-
mendation (66).
If bleeding occurs in a VKA-treated patient with an
INR of 2 to 3, the clinician should avoid the tempta-
tion to lower the INR goal, due to increased risk of
thromboembolic events with an INR <2 (67). In pa-
tients with bleeding and a normal INR, knowledge of
the TTR (68) may be helpful.
DOAC-TREATED PATIENTS. Minor bleeding in a
DOAC-treated patient presents a unique challenge.
Reducing the dose of the DOAC also may reduce
stroke prevention beneﬁts. Changing to an alterna-
tive DOAC in cases of minor bleeding may be an op-
tion. If minor gastrointestinal bleeding occurs in a
patient taking dabigatran or rivaroxaban, the patient
should switch to apixaban or edoxaban 30 mg,
because gastrointestinal bleeding is more common
with dabigatran (33) and perhaps with rivaroxaban
(34) than the other 2 agents. Other patients might
beneﬁt from a switch from a DOAC to a VKA.
No clinical trials currently address the question
of administration of either warfarin or a DOAC
following major bleeding. However, if a patient at high
risk for stroke has a major bleeding episode associated
with VKA and a normal INR, alternative therapies
might be considered. Clinical trials of direct thrombin
inhibitors and FXa inhibitors in stroke prevention in
AF have consistently shown a >50% reduction in CNS
bleeding with the newer agents compared with
warfarin, although the mechanism is uncertain.
CONCOMITANT COMPLEX DISEASE STATES
THAT OCCUR IN AF PATIENTS TAKING OACT
Patients with AF requiring OACT frequently have
comorbid conditions that increase risks of bleeding,affect the risk–beneﬁt ratio of anticoagulation, or
require additional therapy such as antiplatelet
agents. The evolution of therapy in such patients is
ongoing. This is especially true with the use of DOACs
plus antiplatelet therapy (either single or dual).
Combining antiplatelet agents with anticoagulant
agents increases the risk of bleeding. In the RE-LY
(Randomized Evaluation Of Long-Term Anticoag-
ulation Therapy) trial (20), the risk of major bleeding
increased from 2.8% to 4.8%/year when antiplatelet
agents were added to warfarin. The risk of major
bleeding was 2.6%/year with dabigatran 150 mg twice
daily (bid), but increased to 4.4%/year with the
addition of antiplatelet agents. A similar analysis
from the ARISTOTLE (Apixaban for Reduction of
Stroke and Other Thromboembolic Events in Atrial
Fibrillation) trial noted increased bleeding when
aspirin was used in conjunction with either warfarin
or apixaban, although the absolute bleeding risk was
higher with the combination of aspirin and warfarin
compared with aspirin and apixaban (69).
Two ongoing trials may inform the question. The
RE-DUAL PCI (Randomized Evaluation of Dual Ther-
apy with Dabigatran vs. Triple Therapy Strategy with
Warfarin in patients with non-valvular AF that
have undergone PCI with stents [NCT02164864]) will
evaluate clinically-relevant bleeding and thrombo-
embolic events in patients treated with dabigatran
plus a P2Y12 inhibitor compared with the current
standard of warfarin plus dual antiplatelet therapy
(DAPT). The PIONEER-AF PCI (Open-label, Random-
ized, Controlled, Multicenter Study Exploring Two
Treatment Strategies of Rivaroxaban and a Dose-
Adjusted Oral Vitamin K Antagonist Treatment Strat-
egy in Subjects with Atrial Fibrillation Who Undergo
Percutaneous Coronary Intervention [NCT01830543])
will compare clinically-signiﬁcant bleeding in 3 arms of
therapy: 1) rivaroxaban 15-mg daily plus a P2Y12
inhibitor; 2) rivaroxaban 2.5-mg bid plus a P2Y12 in-
hibitor and aspirin 75 to 100 mg daily; or 3) a VKA
adjusted to an INR of 2 to 3, plus a P2Y12 inhibitor and
aspirin 75 to 100 mg daily.
RECENT CORONARY STENT AND
NEW-ONSET AF
AF occurs in 5% to 10% of patients with MI and is
associated with higher mortality compared with pa-
tients without AF (70). If stroke risk is low on the
basis of CHA2DS2-VASc score, then such patients
could be treated with DAPT without the addition of
anticoagulation. Observational data from the Danish
registry (18) suggest that anticoagulant agents plus
clopidogrel appear to be safer than triple therapy,
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been evaluated in randomized trials. Data from an
open-label randomized trial in PCI patients (71)
reported less bleeding and no increase in ischemic
complications in patients treated with clopidogrel
plus VKA compared with triple therapy. However,
larger, blinded studies are needed to conﬁrm these
ﬁndings. In patients who require triple therapy, the
use of bare-metal stents should be encouraged, and
the duration of triple therapy should be kept as
short as possible.
ELECTIVE STENTING IN PATIENTS
WITH ESTABLISHED AF TAKING
ANTICOAGULANT AGENTS
In patients with established AF taking warfarin who
require elective stenting, concomitant glycoprotein
IIb/IIIa inhibitors should generally be avoided. Radial
access and bare-metal stenting are preferred, as the
former reduces access site bleeding and the latter
minimizes the duration of triple therapy. As the
duration of DAPT shortens with newer-generation
drug-eluting stents, this approach is changing and
clinical trials are ongoing. Previously, such patients
may have been transitioned to warfarin, but these
studies may affect this approach. If triple therapy
(including VKA) is used, low-dose aspirin plus clopi-
dogrel is recommended in lieu of ticagrelor or prasu-
grel, because bleeding risks with VKA in conjunction
with ticagrelor or prasugrel are higher than with clo-
pidogrel. A lower-target INR for warfarin (2.0 to 2.5)
should be considered (72). A recent European
Consensus paper (73) suggests a 3-phase approach in
patients with AF and elective stenting. Patients at high
stroke and high bleeding risk (CHA2DS2-VASc $2 and
HAS-BLED $3) should receive 4 weeks of triple ther-
apy, up to 12 months of clopidogrel or aspirin plus an
anticoagulant, and lifetime anticoagulation with or
without an antiplatelet drug. Patients at lower stroke
and bleeding risk (CHA2DS2-VASc of 1 and HAS-BLED
0 to 2) should receive 4 weeks to 6 months of triple
therapy, up to 12 months of clopidogrel or aspirin plus
an anticoagulant, and lifetime anticoagulation.
ACUTE CORONARY SYNDROMES IN
PATIENTS WITH ESTABLISHED AF TAKING
ANTICOAGULANT AGENTS
Low-dose rivaroxaban (2.5 mg bid) for acute coronary
syndromes (ACS) is approved in Europe as adjunctive
therapy. This dose may not be optimal for the pre-
vention of stroke in patients with AF, and rivaroxaban
is not approved for this indication in the United
States. Temporary discontinuation of DOAC shouldbe considered in patients who are on DOACs at
the time of an ACS, and if either ticagrelor or prasugrel
is administered, because bleeding risks with these
agents plus DOACs are unknown. Low-dose is prefer-
able to full-dose aspirin. Bivalirudin may be a prefer-
able acute anticoagulant, due to bleeding risk
in the face of residual DOAC effect. Parenteral anti-
coagulation with heparin can be undertaken after
DOAC effect has dissipated (16). Bare-metal stenting
and a radial approach is preferable (59). Recent ACC/
American Heart Association ACS guidelines state that
anticoagulation may be interrupted at the time of
procedure and that it “may be reasonable” to consider
clopidogrel and anticoagulant agents in lieu of triple
therapy (2). The European Consensus paper (74) sug-
gested a similar 3-phase approach in ACS, in which the
patients at highest risk of both stroke and bleeding
receive 4 weeks of triple therapy followed by up to
12 months of a single antiplatelet drug plus anti-
coagulation, and patients at low risk receive 6 months
of triple therapy followed by up to 12 months of a
single antiplatelet drug plus anticoagulation.
PATIENTS WITH ESTABLISHED AF TAKING
ANTICOAGULANT AGENTS WITH
MEDICALLY-MANAGED CORONARY DISEASE
Although patients with medically-managed coronary
artery disease following ACS may beneﬁt from dual
antiplatelet therapy (74), treatment must be individ-
ualized in patients who are concomitantly on anti-
coagulant agents. The WARIS II (Warfarin-Aspirin
Reinfarction II) trial demonstrated a reduction in
subsequent MI rates with warfarin and aspirin
compared with warfarin alone (75), although it should
be noted that this was not an AF trial. Data from the
ACTIVE W (Atrial Fibrillation Clopidogrel Trial with
Irbesartan for Prevention of Vascular Events) (76) also
support the use of warfarin instead of antiplatelet
therapy in stable CAD by showing that the MI rate in
AF patients assigned to warfarin was similar to those
assigned to aspirin plus clopidogrel. In patients with
stable CAD with AF and an ACS >1 year previously,
care should be individualized; single antiplatelet
therapy or no antiplatelet therapy with anti-
coagulation may be preferred options (2).
PATIENTS WHO DEVELOP AF >1 MONTH
AFTER BARE-METAL STENT OR >6 MONTHS
AFTER DRUG-ELUTING STENT
Data are conﬂicting about whether patients with sta-
ble CAD should be treated with a DOAC or warfarin
alone, assuming this is warranted on the basis of
CHA2DS2-VASc score. In the RE-LY trial (31), there was
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gested an association with direct thrombin inhibitors
and MI (77). However, ischemic events were not
increased in RE-LY (78), and a “real world” Danish
study of dabigatran use did not suggest an increased
frequency of MI (79). Similarly, a survey of 134,414
Medicare patients (37,587 patient-years) treated with
dabigatran or warfarin for nonvalvular AF showed no
increase in MI with dabigatran (80). Figures 4A and 4B
summarize recommendations for OACT with various
coronary artery disease conditions.
PATIENTS WITH CEREBRAL VASCULAR DISEASE
AND ATRIAL AF PATIENTS NOT PREVIOUSLY
TAKING ANTICOAGULANT AGENTS. Patients pre-
senting with acute ischemic stroke or transient is-
chemic cerebral attack of presumed cardioembolic
origin should receive anticoagulation therapy. The
timing and initiation of therapy depends upon the size
of the stroke and the perceived risk of hemorrhagic
transformation (66). In such patients, all DOACs may
be preferable to warfarin because of the universally
reduced risk of ICH. Although this is true in the
convalescent phase of presumed thromboembolic
stroke (after >1 month), it has not been studied in the
acute phase of such strokes. New American Heart As-
sociation/American Stroke Association guidelines
recommend individualized therapy with VKA (Class I,
Level of Evidence: A), apixaban (Class I, Level of Evi-
dence: A), dabigatran (Class I, Level of Evidence: B),
or rivaroxaban (Class IIa, Level of Evidence: B) (66).
The European Society of Cardiology AF guidelines
suggest the use of DOAC rather than VKA in most
patients with nonvalvular AF on the basis of net
clinical beneﬁt (Class IIa recommendation) (81).
Because of the rapid onset of action, bridging therapy
with low-molecular-weight heparin is not required.
For patients unable to take anticoagulant agents,
aspirin is an alternative option, and the addition of
clopidogrel might be reasonable. Two clinical trials
of DOACs compared with aspirin in patients with
embolic strokes of undetermined source (RE-SPECT
ESUS [Dabigatran Etexilate for Secondary Stroke
Prevention in Patients With Embolic Stroke of Un-
determined Source] and NAVIGATE ESUS [Rivarox-
aban Versus Aspirin in Secondary Prevention of
Stroke and Prevention of Systemic Embolism in Pa-
tients With Recent Embolic Stroke of Undetermined
Source]) are currently recruiting patients (82,83).
Previous studies have demonstrated a high preva-
lence of AF detected by prolonged monitoring in pa-
tients presenting with cryptogenic transient ischemic
attack or stroke (66,84). Anticoagulation strategies in
this subset of patients have not been rigorously tested
for risk and beneﬁt.PATIENTS PREVIOUSLY MAINTAINED
TAKING OACT PRESENTING WITH
ACUTE ISCHEMIC STROKE
In patients previously maintained on DOACs, the
balance of risks versus beneﬁts of thrombolytic
therapy for acute ischemic stroke is unclear. If there
is uncertainty about the time since last administra-
tion of the DOAC or if blood studies (e.g., PTT for
dabigatran or PT for FXa inhibitors) indicate residual
drug effect, thrombolysis should generally not be
offered. In patients treated with warfarin, the risk
of ICH with use of recombinant tissue plasmin-
ogen activator appears to be low when the INR
is #1.7 (85).
PATIENTS IN CONVALESCENT PHASE OF
ISCHEMIC STROKE TREATED WITH VKAs
In theory, patients presenting with an ischemic stroke
and a therapeutic INR represent a drug failure of VKA
and may be candidates for DOACs. Patients with
stroke $2 weeks prior to presentation appear to have
the same relative beneﬁts of DOAC versus warfarin
(86,87). If early initiation of a DOAC is contemplated
in a patient previously taking warfarin, it would seem
prudent to allow the effect of warfarin to dissipate
prior to initiating therapy.
PATIENTS WITH HEMORRHAGIC STROKE
TAKING OACT
Hemorrhagic stroke is a complication of anticoagulant
therapy. VKAs account for 12% to 14% of patients with
ICH (88). Anticoagulant agents should be immedi-
ately discontinued, and efforts to reverse anti-
coagulation should be undertaken as previously
described. Although patients who develop hemor-
rhagic stroke on warfarin could theoretically be can-
didates for a DOAC in the convalescent phase, this
hypothesis is untested, as most DOAC studies exclude
patients with prior ICH. Package labeling for both
VKAs and DOACs state that ICH is a contraindication
for anticoagulation unless the cause of the hemor-
rhage has been identiﬁed and corrected. According to
the stroke guidelines, patients at high risk for recur-
rent hemorrhage may be considered candidates for
antiplatelet therapy in lieu of anticoagulation. (Class
IIb, Level of Evidence: B) (66).
PATIENTS WITH SIGNIFICANT
CAROTID STENOSIS AND AF
Patients with carotid stenosis are often prescribed
antiplatelet therapy for stroke prevention. At this
FIGURE 4 Management of Patients with Both AF and Coronary Stents
AF Patient on Vitamin K Antagonist or
Direct-Acting Oral Anticoagulant
ACS medical management
0-12 months
from ACS
Triple
therapy
(see text)
VKA and
ASA
(see text)
<1 month bare metal stent
New onset AF
Continue DAPT alone
VKA and DAPT
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Score 0 or 1
CHA2DS2-VASc
Score ≥2
New onset AF
Avoid GPIIbIIIa
Prefer VKA or
DOAC alone
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>1 month bare metal stent
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•   Low dose aspirin
•   Radial access
•   If using VKA, consider
    INR target 2.0-2.5
•   Prefer clopidogrel if
    triple therapy
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with or without
single anti-platelet
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possible
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B
(A) Patients taking anticoagulants for AF requiring coronary artery stenting. (B) Patients taking DAPT for coronary artery stent who develop AF. ACS ¼ acute coronary
syndrome(s); AF ¼ atrial ﬁbrillation; ASA ¼ aspirin; BMS ¼ bare-metal stent(s); DAPT ¼ dual antiplatelet therapy; DOAC ¼ direct-acting oral anticoagulant; INR ¼
international normalized ratio; VKA ¼ vitamin K antagonist.
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platelet therapy improves outcomes compared with
anticoagulation alone in patients with AF and carotid
disease. Carotid endarterectomy for which single-
agent antiplatelet therapy is usually prescribed may
be preferred over carotid artery stenting that requires
DAPT (59,89). More data are needed, and this topic is
not addressed in the new stroke guidelines.
PATIENTS WITH PERIPHERAL ARTERY
DISEASE AND AF
There are no data on the combination of DAPT and
anticoagulation in patients with AF and peripheral
artery disease managed with percutaneous inter-
vention (89). Patients with medically-managed pe-
ripheral artery disease are generally prescribed
antiplatelet therapy. The addition of anticoagulation
increases bleeding risk, as demonstrated in the WAVE
(Warfarin Antiplatelet Vascular Evaluation Trial) trial
(88), in which patients with peripheral artery disease
were assigned to warfarin plus an antiplatelet agent
compared with an antiplatelet agent alone. Combined
therapy was not associated with an improvement in
the combined endpoints of either MI, stroke, or car-
diovascular death; or MI, stroke, cardiovascular
death, or severe ischemia (coronary or peripheral
arterial). The risk of life-threatening bleeding, how-
ever, occurred in 4.0% of the combined group and
1.2% of the antiplatelet group. Therefore, the risk–
beneﬁt ratio needs to be estimated when deciding
whether these patients should receive concomitantered Questions
o reduce variations in care and disparities in care.
 in the frail and the elderly
tion / adjustment of DOACs in high-risk subgroups
wing fast quantification of drug levels of the DOACs
lation in patients with liver disease
 on the relationship between laboratory measurement of
agulant activity of DOACs and clinical outcomes
onitor drug concentrations or level of anticoagulation with
to manage the bleeding patient / reversal agents.
ased strategies for management of patients with
nt ACS and AF.
ased strategies for management of patients undergoing
s such as ablation or DC cardioversion.
hared decision making.
rmation on interaction of DOACs with food herbs,
ts and other non-prescription agents.
ce metrics that indicate best practice.antiplatelet therapy and anticoagulation. Single an-
tiplatelet therapy makes good clinical sense under
these circumstances, because the CHARISMA (Clopi-
dogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance) trial (90)
of aspirin alone compared with clopidogrel plus
aspirin in patients at high risk for cardiovascular
events demonstrated that the addition of clopidogrel
did not reduce the rate of the primary endpoint of MI,
stroke, or cardiovascular death, but that bleeding
increased with DAPT.
THE USE OF DOACs IN PATIENTS WITH
MECHANICAL HEART VALVES AND IN THE
SETTING OF CARDIAC SURGERY
The RE-ALIGN (Randomized, Phase II Study to Eval-
uate the Safety and Pharmacokinetics of Oral Dabi-
gatran Etexilate in Patients After Heart Valve
Replacement) study (91) tested high-dose dabigatran
as an alternative to warfarin in patients with me-
chanical heart valves. This study was stopped early
due to excessive bleeding and higher thromboem-
bolic events in patients treated with dabigatran. The
rapid onset of action of dabigatran in the post-
operative cardiac surgery setting appears to pose a
risk of serious bleeding, particularly pericardial
bleeding requiring reoperation. Until further results
are available, the use of all DOACs should be avoided
for patients with mechanical prosthetic valves
outside of a clinical trial. The FDA’s prescribing in-
formation for the DOACs are even more restrictive,
stating that they should be avoided in all prosthetic
valves, although DOACs were used in patients with
bioprosthetic valves in several AF clinical trials. The
data from RE-ALIGN with high-dose dabigatran raised
concern for the use of these drugs in the immediate
cardiac post-operative surgical setting (91).
DOACs AT THE TIME OF CARDIOVERSION
Patients who have AF or atrial ﬂutter lasting >48 h are
required to have therapeutic INR (2 to 3) for 3 to
4 weeks prior to cardioversion regardless of method
(pharmacological or electrical) or CHA2DS2-VASc
score (2,92–94). Alternatively, for patients who have
not been taking 3 to 4 weeks of continuous thera-
peutic VKAs, transesophageal echocardiography is
reasonable prior to cardioversion (2,95). With VKAs,
awaiting therapeutic INRs weekly up to the time of
cardioversion has led to delays in cardioversion (96).
Three major randomized clinical trials have eval-
uated subsets of patients who underwent cardio-
version (RE-LY, ROCKET AF [Rivaroxaban Once
Daily Oral Direct Factor Xa Inhibition Compared with
J A C C V O L . 6 5 , N O . 1 3 , 2 0 1 5 Kovacs et al.
A P R I L 7 , 2 0 1 5 : 1 3 4 0 – 6 0 Practical Anticoagulation in Patients With AF
1357Vitamin K Antagonist for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation], and ARIS-
TOTLE) (33–35). A prospective study involving the
use of rivaroxaban has also been published (97). In
all studies, the risk of stroke was low in the weeks
following cardioversion and was comparable to that
with VKA. Of note is the fact that transesophageal
echocardiography did not reduce the rate of throm-
boembolic events (98).
On the basis of these data, for patients with AF or
atrial ﬂutter of unknown duration, or duration $48 h,
anticoagulation with DOACs is required for $3 weeks
prior to cardioversion and should be continued for
$4 weeks post-cardioversion (2).
THE ROLE OF DOACs IN AF ABLATION
Current recommendations for the prevention of
stroke at the time of AF ablation are for continuous
VKA (warfarin) anticoagulation with a low-level
therapeutic range (2.0 to 2.5). Because it is difﬁcult
to maintain an INR within this narrow range, DOACs
may assume a more important role. Single-center
and multicenter studies have examined the efﬁcacy
and safety of DOACs compared with uninterrupted
warfarin in patients undergoing AF ablation (99–104).
In general, centers and operators are either tran-
sitioning patients to warfarin for the periprocedural
period or stopping the DOAC 1 to 2 days prior to
procedure without bridging (105).
A prospective-matched, multicenter, observational
study of 290 patients compared therapeutic warfarin
(2 to 3.5) with dabigatran 150 mg bid for 3 weeks prior
to ablation (with dabigatran held morning of proce-
dure and resumed 3 h post-procedure). A signiﬁcant
increase in composite bleeding and thromboem-
bolic complications was noted with dabigatran (100).
Several studies in which dabigatran was held at
least 24 h prior to procedure and restarted 4 to 22 hlater did not show any signiﬁcant bleeding or throm-
boembolic complications compared with warfarin.
These data suggest dabigatran should be interrupted
$24 h prior to the procedure to prevent signiﬁcant
bleeding (101–103).
A multicenter, prospective study evaluated the
safety and efﬁcacy of rivaroxaban in comparison with
uninterrupted warfarin therapy during AF ablation.
Rivaroxaban was held 16 h prior to ablation and
resumed 6 h after hemostasis was obtained. There
was no difference in major or minor bleeding com-
plications. One transient ischemic attack occurred in
each group, and no periprocedural stroke or deaths
occurred in either group. The authors concluded that
rivaroxaban, with the dose held on the day of proce-
dure, appears to be equally safe and effective when
compared with uninterrupted warfarin (100).
CONCLUSIONS
Roundtable discussion of 4 major topics related to the
integration of DOACs into clinical practice resulted in
consensus in many areas, but questions and chal-
lenges in others. A poll of the participants was
unanimous in the opinion that the stakeholder groups
need to continue dialogue about the integration of
these drugs into practice. Figure 5 includes a list of
unanswered questions.
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